Shots: NICE has recommended Ajovy in its final appraisal document (FAD) to prevent migraine in patients with chronic migraine who have not responded to at least three prior preventive drug […]readmore
Tags : AJOVY
Shots: The two P-II/III studies involve assessing of Ajovy vs PBO in patients with chronic and episodic migraine respectively The two P-II/III studies resulted in meeting its 1EPs and 2EPs […]readmore
Shots: AJOVY (remanezumab-vfrm) is evaluated in two P-III trial enrolling patients with disabling migraine, administering AJOVY alone and in combination with oral preventive treatments, showing reduction in monthly migraine days […]readmore